Busilvex 60mg10ml concentrate for solution for infusion ampoules United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

busilvex 60mg10ml concentrate for solution for infusion ampoules

pierre fabre ltd - busulfan - solution for infusion - 6mg/1ml

Navelbine 20mg capsules United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

navelbine 20mg capsules

pierre fabre ltd - vinorelbine tartrate - oral capsule - 20mg

Navelbine 30mg capsules United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

navelbine 30mg capsules

pierre fabre ltd - vinorelbine tartrate - oral capsule - 30mg

Clarelux 500micrograms/g foam United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

clarelux 500micrograms/g foam

pierre fabre ltd - clobetasol propionate - cutaneous foam - 500microgram/1gram

Rosiced 0.75% cream United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

rosiced 0.75% cream

pierre fabre dermo-cosmetique - metronidazole - cutaneous cream - 7.5mg/1gram

Navelbine 80mg capsules United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

navelbine 80mg capsules

pierre fabre ltd - vinorelbine tartrate - oral capsule - 80mg

Javlor 250mg10ml concentrate for solution for infusion vials United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

javlor 250mg10ml concentrate for solution for infusion vials

pierre fabre ltd - vinflunine ditartrate - solution for infusion - 25mg/1ml

Javlor 50mg2ml concentrate for solution for infusion vials United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

javlor 50mg2ml concentrate for solution for infusion vials

pierre fabre ltd - vinflunine ditartrate - solution for infusion - 25mg/1ml

NAVELBINE ORAL vinorelbine 80mg (as tartrate) capsule blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

navelbine oral vinorelbine 80mg (as tartrate) capsule blister pack

pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 110.8 mg (equivalent: vinorelbine, qty 80 mg) - capsule, soft - excipient ingredients: ethanol; purified water; glycerol; macrogol 400; gelatin; iron oxide yellow; titanium dioxide; medium chain triglycerides; ascorbyl palmitate; phosphatidyl choline; dl-alpha-tocopherol; sorbitol; 1,4-sorbitan; mannitol; hydrogenated starch hydrosylate; hypromellose; propylene glycol; isopropyl alcohol; aluminium chloride; sodium hydroxide; cochineal - non-small cell lung cancer: navelbine oral is indicated for first line treatment of advanced non-small cell lung cancer, as a single agent or in combination.,breast cancer: navelbine oral is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.

NAVELBINE ORAL vinorelbine 30mg (as tartrate) capsule blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

navelbine oral vinorelbine 30mg (as tartrate) capsule blister pack

pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 41.55 mg (equivalent: vinorelbine, qty 30 mg) - capsule, soft - excipient ingredients: ethanol; purified water; glycerol; macrogol 400; gelatin; iron oxide red; titanium dioxide; medium chain triglycerides; ascorbyl palmitate; phosphatidyl choline; dl-alpha-tocopherol; sorbitol; 1,4-sorbitan; mannitol; hydrogenated starch hydrosylate; hypromellose; propylene glycol; isopropyl alcohol; aluminium chloride; sodium hydroxide; cochineal - non-small cell lung cancer: navelbine oral is indicated for first line treatment of advanced non-small cell lung cancer, as a single agent or in combination.,breast cancer: navelbine oral is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.